Fortress Biotech Inc (FBIO)
1.73
-0.03
(-1.70%)
USD |
NASDAQ |
May 15, 14:52
Fortress Biotech Cash from Financing (Quarterly): 43.62M for Dec. 31, 2023
Cash from Financing (Quarterly) Chart
Historical Cash from Financing (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | 43.62M |
| September 30, 2023 | -2.685M |
| June 30, 2023 | -30.38M |
| March 31, 2023 | 22.19M |
| December 31, 2022 | 18.62M |
| September 30, 2022 | 3.746M |
| June 30, 2022 | 2.991M |
| March 31, 2022 | 49.96M |
| December 31, 2021 | 38.94M |
| September 30, 2021 | 6.966M |
| June 30, 2021 | 24.40M |
| March 31, 2021 | 78.69M |
| December 31, 2020 | 37.02M |
| September 30, 2020 | 46.83M |
| June 30, 2020 | 65.81M |
| March 31, 2020 | 22.75M |
| December 31, 2019 | 27.16M |
| September 30, 2019 | 5.552M |
| June 30, 2019 | 61.89M |
| March 31, 2019 | 52.11M |
| December 31, 2018 | -1.692M |
| September 30, 2018 | 9.956M |
| June 30, 2018 | 2.729M |
| March 31, 2018 | 39.66M |
| December 31, 2017 | 20.66M |
| Date | Value |
|---|---|
| September 30, 2017 | 17.14M |
| June 30, 2017 | 54.42M |
| March 31, 2017 | 58.16M |
| December 31, 2016 | 25.95M |
| September 30, 2016 | 17.86M |
| June 30, 2016 | 1.521M |
| March 31, 2016 | -2.427M |
| December 31, 2015 | 40.46M |
| September 30, 2015 | 11.07M |
| June 30, 2015 | 0.026M |
| March 31, 2015 | 9.361M |
| December 31, 2014 | 4.372M |
| September 30, 2014 | -1.437M |
| June 30, 2014 | 0.125M |
| March 31, 2014 | -13.22M |
| December 31, 2013 | 0.387M |
| September 30, 2013 | 45.52M |
| June 30, 2013 | 31.90M |
| March 31, 2013 | 11.35M |
| December 31, 2012 | 0.105M |
| September 30, 2012 | 13.93M |
| June 30, 2012 | 26.48M |
| March 31, 2012 | 0.00 |
| December 31, 2011 | 0.113M |
| September 30, 2011 | -0.006M |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (Quarterly) Range, Past 5 Years
-30.38M
Minimum
Jun 2023
78.69M
Maximum
Mar 2021
27.58M
Average
24.40M
Median
Jun 2021
Cash from Financing (Quarterly) Benchmarks
| Journey Medical Corp | 19.21M |
| Avenue Therapeutics Inc | 3.946M |
| Mustang Bio Inc | 3.956M |
| Checkpoint Therapeutics Inc | 12.79M |
| Viking Therapeutics Inc | 606.04M |
Cash from Financing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -34.94M |
| Cash from Investing (Quarterly) | -0.063M |
| Free Cash Flow | -136.32M |
| Free Cash Flow Per Share (Quarterly) | -3.252 |
| Free Cash Flow to Equity (Quarterly) | -50.06M |
| Free Cash Flow to Firm (Quarterly) | -33.63M |
| Free Cash Flow Yield | -972.1% |